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Chieti, ItalyObjectives This study sought to hypothesize that the higher risk of myocardial infarction (MI)
documented after a routine double drug-eluting stent (DES) strategy (DDS) compared with a single
DES strategy (SDS) with provisional stenting in percutaneous coronary interventions (PCI) of
bifurcation lesions is driven by an increased rate of DES thrombosis.
Background The results of currently available randomized, controlled trials (RCTs) were inconclusive
in the choice between SDS and DDS. Meta-analyses have shown an increased risk of MI in the DDS
group, without identifying the underlying mechanism(s).
Methods We performed a meta-analysis of 12 major (>100 patients) studies of bifurcation DES PCI:
5 RCTs and 7 nonrandomized observational studies, for a total of 6,961 patients. Random-effects
models were used to calculate summary risk ratios (RRs). As a primary endpoint, we assessed the RRs
and 95% conﬁdence intervals (CIs) of deﬁnite DES thrombosis; death, MI, and target vessel
revascularization (TVR) were evaluated as secondary endpoints.
Results Compared with SDS, DDS had an increased risk of DES thrombosis (RR: 2.31; 95% CI: 1.33 to
4.03) and MI (RR: 1.86; 95% CI: 1.34 to 2.60). Mortality (RR: 1.18; 95% CI: 0.85 to 1.65) and TVR (RR: 1.02;
95% CI: 0.80 to 1.30) were similar. The RRs of MI and DES thrombosis were associated (p ¼ 0.040).
Conclusions In PCI of coronary bifurcations, SDS should be the preferred approach, as DDS is
associated with an increased risk of MI, likely driven by DES thrombosis. (J Am Coll Cardiol Intv
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688Percutaneous coronary interventions (PCI) in the treatment
of coronary bifurcation lesions has been associated with
worse in-hospital and long-term outcomes compared with
nonbifurcation lesions (1,2). In the drug-eluting stent
(DES) era, several randomized, controlled trials (RCTs)
(3–9) and nonrandomized, observational studies (nROSs)
(10–17) tried to identify the optimal strategy for the treat-
ment of bifurcations between a single DES strategy (SDS)
(stenting in the main vessel with provisional stenting of the
side branch only in bail out) and a double DES strategySee page 696(DDS) (deployment of 2 DESs in whatever technique used).
Having the vast majority of these studies show no difference
among the 2 strategies, several meta-analyses of RCTs wereAbbreviations
and Acronyms
CI = conﬁdence interval
DDS = double drug-eluting
stent strategy
DES = drug-eluting stent(s)
MI = myocardial infarction
nROS = nonrandomized,
observational study
PCI = percutaneous coronary
intervention
RCT = randomized, controlled
trial
RR = relative risk
SDS = single drug-eluting
stent strategy
TVR = target vessel
revascularizationperformed (18–25); a signiﬁ-
cantly higher incidence of
myocardial infarction (MI) with
the DDS was documented,
without identifying the under-
lying mechanism(s).
We hypothesized that the
increase in adverse outcomes re-
ported with DDS would be
driven by a signiﬁcant increase in
the rate of DES thrombosis. To
test such a hypothesis, we per-
formed a meta-analysis of major
available RCTs and nROSs
comparing SDS and DDS.
Methods
Search strategy and selection cri-
teria. We searched PubMed, theClinical Trials Registry (www.clinicaltrials.gov), as well as
abstracts from meetings of major cardiology societies. The
search terms used were “coronary,” “bifurcat*,” and “stent.”
Websites, including cardiosource.com, TCTMD.com, the-
heart.org, and escardio.org, were also searched for relevant
materials. References of the articles identiﬁed in this manner
were also searched to locate additional references not identi-
ﬁed by the search strategy thatmight be useful for the purpose.
Two of the authors (A.C. and F.R.) performed screening
of titles and abstracts, reviewed full-text articles, and
determined their eligibility. The search was performed for
the period January 2001 through December 2011 and was
limited to the English-language literature. Reviewers were
not blinded to study authors or outcomes. Disagreement was
resolved by contact with the corresponding authors or by
consensus. We included only studies with >100 patients
with a follow-up duration of at least 6 months.Among 845 identiﬁed citations, 815 were considered
irrelevant for our purpose; in addition to meta-analyses,
papers describing the use of bare-metal stents and 2 small
studies, although relevant, were excluded, 1 because of
non-English language (26) and 1 (27) because data were
reported only as percentages (Fig. 1).
Both RCTs and nROSs comparing SDS and DDS in the
treatment of bifurcating lesions were included in the analysis.
Because bifurcation morphology was not systematically
reported, we decided to include all studies referring to the
treatment of bifurcating lesion, however classiﬁed.
Data collection and quality assessment. Relevant informa-
tion extracted from the studies included the type of study
(RCT or nROS), year of publication, treatment allocation,
age, sex, acute coronary syndrome, diabetes, length of the
implanted stents, use of IIb-IIIa glycoprotein inhibitors, ﬁnal
“kissing” balloon, “true” bifurcation with disease involvement
of both main and side branches, deﬁned by Medina et al. (28)
as subgroup 1,1,1 or 0,1,1, and 1,0,1, follow-up duration, type
of DES, DDS technique, crossover from SDS to DDS, and
recommended duration of double antiplatelet therapy.
Absolute numbers were recalculated when percentages
were reported.
The quality of each study was assessed by evaluating
speciﬁc elements of each study design (29), with Jadad
(30) and Newcastle-Ottawa (31) scales for RCTs and
nROSs, respectively (see Supplementary Tables S1 and
S2).
Outcomes. The endpoints of interest in the overall analysis
were DES thrombosis as the primary endpoint, and death,
MI, and target vessel revascularization (TVR) as secondary
endpoints. Stent thrombosis was accepted when the “deﬁ-
nite” criteria of the Academic Research Consortium (32)
were met, whenever speciﬁed. Mortality was accepted as re-
ported. MI was deﬁned by studies as periprocedural or
during follow-up: few studies gave precise deﬁnitions or
how MI was diagnosed, and, when available, MI diagnostic
criteria varied widely. TVRwas deﬁned according to the study
protocols, and, if not reported, we used target lesion revas-
cularization instead. The numbers of events in each studywere
extracted, when available, on the basis of an intention-to-treat
approach.
Outcome data were extracted by one of the authors (F.R.)
and checked by another author (A.C.).
Statistical analysis. Categorical variables were reported as
number and percentage, and continuous variables were
presented as mean  SD. Normal distribution of variables
was assessed, when needed, by the 1-sample Kolmogorov-
Smirnov test. From the abstracted data, the relative risk
(RR) was calculated using the Mantel-Haenszel method
for each study outcome to allow pooling of similar out-
comes. The average effects for the outcomes and 95%
conﬁdence interval (CI) were obtained using a random-
effects model.
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Figure 1. Flow chart Showing the Process of Study Selection
BMS ¼ bare metal stent; DDS ¼ double drug-eluting stent strategy;
pts ¼ patients; SDS ¼ single drug-eluting stent strategy.
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689Heterogeneity of effect across studies was assessed by
Cochrane Q chi-square statistics and I2 statistics (33). Lack
of homogeneity was considered for Cochrane Q chi-square
test p values 0.10 and for I2 statistics 50%. When
heterogeneity was judged signiﬁcant, the pooled RR was
calculated with the DerSimonian-Laird method for random
effects (34). We report the meta-analysis results in classic
Forest plots, with point estimates and 95% CIs for each trial
and for the studies overall. We also performed a sensitivity
analysis to evaluate whether the summary estimate of the
effect could have been signiﬁcantly affected by a single study.
To this purpose, pooled estimates were recalculated, using
a random-effects model, by omitting 1 study at a time. The
likelihood of publication bias was assessed graphically
by generating a funnel plot for the endpoints of MI and
DES thrombosis and evaluated by Egger’s test of intercept
(p value for signiﬁcant asymmetry <0.1).
We also performed an explorative meta-regression anal-
ysis using a mixed-effects model to assess the effect of
selected variables (type of study, age, sex, diabetes, acute
coronary syndrome, “true” bifurcation, use of glycoprotein
IIb-IIIa inhibitors, total length of implanted DES, ﬁnal
“kissing” balloon, follow-up duration, and recommended
duration of double antiplatelet therapy) on the risk of DES
thrombosis. The RRs of DES thrombosis and MI for
individual trials were log-transformed before being used as
independent variables in the linear meta-regression analysis
on MI event. Statistical analyses were performed using
STATA version 11.0 (StataCorp, College Station, Texas).
Results
We selected 12 studies (5 RCTs and 7 nROSs) for a total
of 6,961 patients, 1,868 treated with DDS and 5,093 with
SDS.
Figure 2. Outcomes in Randomized and Observational Studies
Forest plot with individual and summary estimates of the relative risk (RR) and 95% conﬁdence interval (CI) of drug-eluting stent (DES) thrombosis (A), overall
mortality (B)
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690The main characteristics of the studies are summarized in
Table 1. The mean patient age ranged from 62 to 68 years, and
diabetes mellitus prevalence ranged from 12% to 45%. Dualantiplatelet therapy (with both clopidogrel 75 mg once daily
or ticlopidine 250 mg twice daily) was recommended for
a minimum of 3 to 12 months, depending on the study design.
Figure 2. Continued
myocardial infarction (C), and target-vessel revascularization (TVR) (D) among patients treated with DDS compared with SDS. Diamond size is proportional to study
weight in random-effects model. For study acronyms, refer to Table 1. *Weights are from random-effects analysis. Trials' acronyms as in Table 1. Other abbreviations as
in Figure 1.
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691The DDS group had a higher risk of the primary
endpoint deﬁnite DES thrombosis (RR: 2.31; 95% CI: 1.33
to 4.03) (Fig. 2A), without signiﬁcant heterogeneity amongstudies (Cochrane Q p ¼ 0.473; I2 ¼ 0%). Subgroup
analysis, again performed despite the absence of heteroge-
neity, showed that a signiﬁcantly increased risk was limited
Figure 4. Association Between Log-Transformed Risk of DES
Thrombosis and Myocardial Infarction
The size of each circle represents the precision of each estimate (the
inverse variance of the log RR in the trial), and the line is the best ﬁt for
the meta-regression model. Randomized, controlled trials (ﬁlled circles);
nonrandomized observational studies (open circles). Abbreviations as in
Figures 2 and 3.
Figure 3. Publication Bias
Begg’s funnel plot of studies according to the logarithmic relative risk (Ln RR)
of drug-eluting stent thrombosis (A) and myocardial infarction (B) versus SE.
Lower SE indicates better precision and larger study size.
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692to nROSs (RR: 2.35; 95% CI: 1.13 to 5.78), whereas RCTs
showed only a trend toward this direction (RR: 2.01; 95%
CI: 0.77 to 5.23).
All-cause mortality was similar in the 2 treatment groups
(RR: 1.18; 95% CI: 0.85 to 1.65) (Fig. 2B).
MI occurred more frequently in the DDS group (RR:
1.86; 95% CI: 1.34 to 2.35) (Fig. 2C). A subgroup analysis,
performed despite no signiﬁcant heterogeneity among
studies (Cochrane Q p ¼ 0.129; I2 ¼ 32.69%), conﬁrmed
an increased risk of MI after DDS in both RCTs (RR: 1.88;
95% CI: 1.35 to 2.62) and nROSs (RR: 1.85; 95% CI: 1.03
to 3.32).
TVR was similar in the 2 groups (RR: 1.02; 95% CI: 0.80
to 1.30) (Fig. 2D).
The post hoc sensitivity analysis showed that no single
study signiﬁcantly affected the pooled estimates of RR for
DES thrombosis and MI (Supplementary Figs. S1 and S2).
Moreover, visual inspection of the funnel plot for MI(Fig. 3A) and DES thrombosis (Fig. 3B) did not reveal
asymmetry; in support of this ﬁnding, publication bias or
“small study effect” were likely excluded by Egger’s test of
intercept (DES thrombosis intercept ¼ 0.34, p ¼ 0.786; MI
intercept ¼ 0.63, p ¼ 0.204). The meta-regression analysis
failed to show any association between the overall risk of
DES thrombosis and the type of study (classiﬁed as RCT or
nROS) (y ¼ 0.47 þ 0.22x; p ¼ 0.733) or any of the other
selected variables. We documented a signiﬁcant association
between the RR of DES thrombosis and MI among the
various studies (p ¼ 0.040) (Fig. 4).
Discussion
The present meta-analysis of RCTs and nROSs conﬁrms
that in patients undergoing PCI for coronary bifurcation
lesions, DDS is associated with similar mid-term mortality
and TVR, but an increased MI rate compared with SDS.
Our data extend previous knowledge by showing that the
increased risk of MI is associated with (and, our inference,
driven by) a higher risk of DES thrombosis with DDS.
Coronary bifurcations are commonly considered complex
lesions, and their optimal interventional treatment may
require initial adjunctive debulking, double guidewire place-
ment, recrossing of stent struts toward the side branch, and
ﬁnal “kissing” balloon inﬂation. Therefore, in the treatment
of multivessel disease, bifurcations may become a crucial
obstacle to complete revascularization, with a potentially
negative impact on long-term outcome (35). However, the
technique of stent deployment has not been fully standard-
ized, with a wide range of use of crush, culotte, and T
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693stenting among various reports (Table 1), even for PCI of
unprotected left main bifurcation disease, currently investi-
gated as a valuable alternative to bypass surgery (36,37).
The introduction of DES has been thought to improve
outcomes by decreasing restenosis and TVR compared with
bare-metal stents, even in the bifurcation subset (38).
However, DES can exert an optimal effect on vessel wall
healing only if the drug is released for the entire lesion
length; incomplete coverage of the carina has therefore been
postulated as a possible cause of restenosis in bifurcating
lesions (39). To overcome this problem and to obtain full
coverage of the bifurcating lesion, different complex tech-
niques with double DES have been developed as dedicated
stents (2), but the advantage of routine stenting of the side
branch for every anatomic subset has been severely criticized.
Currently available guidelines (40) recommend SDS as
the preferred approach when the side branch is not large and
has only mild or moderate focal disease at the ostium (class I,
level of evidence A); DDS is reasonable in cases of complex
bifurcation morphology involving a large side branch, where
the risk of side-branch occlusion is high and the likelihood
of successful side-branch re-access is low (class IIa, level of
evidence B).
Several RCTs (3–9) yielded almost similar outcomes for
DDS compared with SDS, but the studies were mainly
powered for angiographic or combined clinical endpoints.
The most signiﬁcant results were obtained by the recent
DKCRUSH-II (Double Kissing Crush versus Provisional
Stenting Technique for Treatment of Coronary Bifurcation
Lesions) trial (9) that arguably enrolled the most complex
patients in the trials, with lesion lengths >3 times longer
than those in other trials. Here, SDS showed an increased
angiographic restenosis rate in both main and side branches,
and this fostered a higher TVR (14.6%) compared with
DDS (6.5%, p ¼ 0.017); however, the authors reported
a 2.2% thrombosis rate after DDS that was dismissed as
“similar” because, although being >4 times higher than SDS
(0.5%), this difference did not reach statistical signiﬁcance.
Only after combining patient-level data from the Nordic
and the British Bifurcation Coronary Study: Old, New, and
Evolving strategies (BBC-ONE) studies, Behan et al. (24)
documented that SDS was associated with a signiﬁcantly
reduced combined death, MI and TVR (10.1%) compared
with DDS (17.3%, p < 0.001). However, such results were
mainly driven by a higher MI rate in DDS (12.3%) versus
SDS (4.8%, p < 0.001), being mostly periprocedural MIs,
whereas subsequent MIs were only slightly higher in DDS
(2.4%) than in SDS (1.3%, p ¼ NS); DES thrombosis
occurred in 1.3% of DDS and in 0.7% of SDS (p ¼ NS).
Procedure duration, amount of contrast medium used, and
x-ray dose all favored SDS over DDS.
Several meta-analyses of RCTs (18–25) documented an
increased MI risk in patients undergoing DDS, although
authors were not able to discern periprocedural fromsubsequent events because the deﬁnition used to diagnoseMI
was slightly different among studies and the information on
timing was not always speciﬁed. Our report conﬁrms
this ﬁnding, excluding signiﬁcant heterogeneity among the
studies included. Stent thrombosis is an extremely unfavor-
able event, occurring more frequently and associated with
even higher in-hospital and long-term mortality rates when
involving bifurcation than nonbifurcation lesions (41). In our
meta-analysis, a close association between the increased risk
of MI and DES thrombosis was documented (Fig. 4), being
a causal relationship consistent in both RCTs and nROSs.
To date, nometa-analysis has clearly identiﬁed an increased
risk of DES thrombosis after DDS; only a trend toward
a higher risk has been documented, without reaching statis-
tical signiﬁcance (18–25). To disclose whetherDDSwould be
signiﬁcantly associated with an increased risk of DES
thrombosis, we pooled data from both RCTs and nROSs.
Obviously, the mechanisms underlying the increased risk of
DES thrombosis go beyond the stenting technique, as this
may be a surrogate marker for more complex atherosclerotic
disease and more advanced bifurcation involvement.
Study limitations. Although nROSs may be affected by
different limitations (e.g., selection and publication bias, lack
of intention-to-treat data reporting), they reﬂect, on the
other hand, real-world clinical practice in the overall pop-
ulation. Although RCTs may have limited generalizability
to everyday practice, nROSs analyze larger populations and
provide longer follow-up, although in this case, they yielded
mixed results, probably because of the mixed patient selec-
tion; nROSs answer crucial questions that are otherwise
impossible to answer and can produce results with a rele-
vance comparable to that obtained in RCTs, provided
a meticulous quality control of methodology is used. Inclu-
sion of both RCTs and nROSs could represent a source
of data heterogeneity, although in our meta-analysis, this
possibility was excluded for both MI and DES thrombosis
by Cochrane Q chi-square test and I2 statistics.
The risk of DES thrombosis is approximately 2-fold when
patients are treated with DDS, and even higher in another
registry that was not included in the present meta-analysis
because of the lack of detail (27). The signiﬁcant RR of DDS
for DES thrombosis obtained after merging data derived
from nROSs might raise the suspicion of a systematic
overestimation of treatment effect in nROSs. However, the
RR of DES thrombosis with DDS is similar in both RCTs
and nROS (2.17 vs. 2.49, respectively, Fig. 2C); moreover,
the funnel plot showed no asymmetry or “lower left-hand
corner effect” (42), the bias coming from pooling results of
small studies with Egger’s test supporting this ﬁnding
(Fig. 3B). Therefore, the signiﬁcantly increased RR of DES
thrombosis after DDS obtained in the cumulative analysis
must be interpreted as a mere consequence of the higher
overall number of events recorded, leading to narrower
conﬁdence intervals.
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694DES PCI of a bifurcation lesion is a known risk factor for
coronary thrombosis (43). In the nROSs selected for the
present analysis, SDS was used in most cases, but we must
acknowledge that selection bias might be a major limitation
of this analysis because DDS would have been more likely
used in complex anatomic settings, and this choice would
account for an increased risk of DES thrombosis in the
DDS group. All the studies, both RCTs and nROSs, were
included in the present meta-analysis regardless of the
presence or absence of any morphological classiﬁcation;
therefore, we cannot infer whether a differential result can be
applied to the treatment of “true” bifurcations. Plaque
distribution at bifurcation sites signiﬁcantly affects stenting
outcomes, and the presence of plaque in the whole bifur-
cation area is associated with enhanced TVR risk, seemingly
regardless of stent technique and plaque severity (44). In
real-world practice, DDS is sometimes inevitable in the
effort to keep the side patent, especially in the case of a true
bifurcated lesion with a massive plaque burden and a side
branch of considerable size. Most DDS techniques entail the
placement of multiple metal layers, double at best when it
extends to the main vessel, as in the culotte technique, or is
limited to the ostium of the side branch or the carina, as in
V/T stenting or in “kissing” stents, and even triple, as in the
crush technique or its modiﬁcations (45). This complex
ﬁnal stent architecture likely impairs homogeneous metal
strut endothelialization (46) and likely increases the risk of
DES thrombosis. In such cases, there is no consensus as to
whether a ﬁnal “kissing balloons” with simultaneous balloon
inﬂation in both main and side branches might improve
outcome: in general, it seems associated with a reduced TVR
rate in DDS and unnecessary and even harmful in SDS (47).
We must acknowledge a second major limitation.
Although most RCTs, with the exception of 1 study (4), were
based on an intention-to-treat analysis, nROSs showed on-
treatment event reporting. This difference may represent
a confounding element in the pooled analysis. However, overall
crossover rates among RCTs (i.e., the percentage of patients
shifting from SDS to DDS) appear to be acceptably low.
We also recognize that we analyzed TVR, not restenosis,
which was not systematically reported in all studies or was
reported only for the cohort of patients who underwent
follow-up angiography.
We also acknowledge that all the studies included describe
results of ﬁrst-generation DESs, which have recently shown
an increased tendency toward thrombosis compared with
contemporary DESs (48).
A further limitation of the present analysis resides in the
antithrombotic therapy: the use of glycoprotein IIb-IIIa
inhibitors during PCI and the duration of double antiplatelet
therapy (49) in the follow-up differed widely among the
studies (Table 1). Newer thienopyridines have documented
a signiﬁcant reduction of DES thrombosis after PCI per-
formed for acute coronary syndrome (50,51); however, todate, no available data exist on the potential implication of
this beneﬁt in the treatment of bifurcation lesions.
Conclusions
In PCI of coronary bifurcations, routine DDS, DES
implantation in both branches, is associated with an
increased mid-term risk of MI compared with SDSdDES
deployment in the main branch and provisional stenting of
the side branch. The risk of MI is associated with and seems
driven by an increased risk of DES thrombosis. Because of
this likely causal association, when DDS has to be per-
formed, an aggressive antiplatelet therapy should be rec-
ommended, provided that future studies assess whether
more potent antiplatelet therapies would reduce the risk of
DES thrombosis in the setting of bifurcation lesions.Reprint requests and correspondence: Dr. Marco Zimarino,
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